Lonza
global GMP capacity (Lonza Visp/US, Catalent, Thermo Fisher Patheon) that lets a sponsor manufacture in-region without owning a plant.
- Country
- Switzerland
Commercial
Pure-Play CDMO
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| cleanroom-facilities | ✓ | ✓ | — | ✓ |
| consumables | ✓ | ✓ | — | ✓ |
| market-access-commercial | ✓ | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | — | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioproduction CDMO/CMO (biologics/ATMP/mRNA) | therapeutics-platforms | Low | → |
| Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing) | therapeutics-platforms | Low | → |
| Local manufacturing for market access | market-access-commercial | Low | → |
| Media manufacturing (B2B production equipment) | cleanroom-facilities | Low | → |
| Microcarriers for adherent cell cultures | consumables | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.